¼¼°èÀÇ ½Å°æ¿µ¾ç¼º °¢¸·¿°(NK) ½ÃÀå : ÁÖ¿ä Á¶»ç(KOL ÀλçÀÌÆ®) - ½ÃÀå Á¤º¸, ¿ªÇÐ ¹× ½ÃÀå ¿¹Ãø(-2034³â)
Neurotrophic Keratitis (NK) | Primary Research (KOL¢¥s Insight) | Market Intelligence | Epidemiology & Market Forecast-2034
»óǰÄÚµå : 1466818
¸®¼­Ä¡»ç : Mellalta Meets LLP
¹ßÇàÀÏ : 2024³â 02¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 180 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 7,000 £Ü 9,576,000
PPT (Single User License) help
PPT º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1ȸ¿¡ ÇÑÇØ °¡´ÉÇϸç, PPT ³» ÅØ½ºÆ® µîÀÇ Copy °¡´ÉÇÕ´Ï´Ù. Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PPT ÀÌ¿ë ¹üÀ§¿¡ ÁØÇÕ´Ï´Ù.
US $ 9,950 £Ü 13,612,000
PPT (2 - 3 User License) help
PPT º¸°í¼­¸¦ 3¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 3ȸ¿¡ ÇÑÇØ °¡´ÉÇϸç, PPT ³» ÅØ½ºÆ® µîÀÇ Copy °¡´ÉÇÕ´Ï´Ù. Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PPT ÀÌ¿ë ¹üÀ§¿¡ ÁØÇÕ´Ï´Ù.
US $ 13,500 £Ü 18,469,000
PPT (Site License - Up to 10 Users) help
PPT º¸°í¼­¸¦ 10¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 10ȸ¿¡ ÇÑÇØ °¡´ÉÇϸç, PPT ³» ÅØ½ºÆ® µîÀÇ Copy °¡´ÉÇÕ´Ï´Ù. Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PPT ÀÌ¿ë ¹üÀ§¿¡ ÁØÇÕ´Ï´Ù.
US $ 20,200 £Ü 27,635,000
PPT (Enterprise License) help
PPT º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç, PPT ³» ÅØ½ºÆ® µîÀÇ Copy °¡´ÉÇÕ´Ï´Ù. Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PPT ÀÌ¿ë ¹üÀ§¿¡ ÁØÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

½Å°æ¿µ¾ç¼º °¢¸·¿°(NK, Neurotrophic Keratitis) ½ÃÀåÀº ÃÖÃÊÀÌÀÚ À¯ÀÏÇÏ°Ô ½ÂÀÎµÈ Ä¡·áÁ¦ÀÎ Oxervate/cenegermin°ú ¹«¹æºÎÁ¦ Àΰø ´«¹°, ¿¬°í µî°ú °°Àº º¸Á¶ Ä¡·áÁ¦°¡ Å©°Ô ±â¿©Çϰí ÀÖ½À´Ï´Ù. 2034³â±îÁö »õ·Î¿î ½ÅÈï Ä¡·á¹ýÀÇ µµÀÔÀº ½Å°æ¿µ¾ç¼º °¢¸·¿°(NK) Ä¡·áÁ¦ ½ÃÀå¿¡ ±Þ°ÝÇÑ º¯È­¸¦ °¡Á®¿À´Â ÁÖ¿ä ºÐ±âÁ¡ÀÌ µÉ °ÍÀÔ´Ï´Ù. Á¶»ç ´ë»ó ±¹°¡(¹Ì±¹, ÇÁ¶û½º, µ¶ÀÏ, ÀÌÅ»¸®¾Æ, ½ºÆäÀÎ, ¿µ±¹, ÀϺ»)¿¡ ´ëÇÑ ½Å°æ¿µ¾ç°¢¸·¿°(NK) ½ÃÀå ±Ô¸ð´Â 2020-2034³â Á¶»ç±â°£ Áß¿¡ CAGR 11%·Î °í¼ºÀåÀ» ÀÌ·ç°í, 2034³â±îÁö 24¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

½Å°æ¿µ¾ç¼º °¢¸·¿°Àº ½Å°æ À§Ã༺ °¢¸·º´ÁõÀ¸·Îµµ ¾Ë·ÁÁ® ÀÖÀ¸¸ç °¢¸· ¹Î°¨µµ °¨¼Ò¿Í °¢¸· Ä¡À¯·Â ÀúÇϸ¦ Ư¡À¸·Î ÇÏ´Â ÅðÇ༺ ÁúȯÀÔ´Ï´Ù. ÀÌ ÁúȯÀº °¢¸·À» ¼Õ»óµÇ±â ½±°Ô ¸¸µé°í ¹Ý»ç ´«¹°»ùÀ» °¨¼Ò½Ãŵ´Ï´Ù. »óÇǰ¡ ÆÄ±«µÇ¸é Ä¡À¯°¡ Àß µÇÁö ¾Ê¾Æ ±Ë¾ç, °¨¿°, À¶ÇØ, õ°øÀÌ ÀÌÂ÷ÀûÀ¸·Î ¹ß»ýÇÒ ¼ö ÀÖ½À´Ï´Ù.

½Å°æ¿µ¾ç¼º °¢¸·¿° ȯÀÚ´Â »ïÂ÷ ½Å°æ¿¡ ¼Õ»óÀÌ ÀÖ½À´Ï´Ù. ÀÌ·Î ÀÎÇØ °¢¸·ÀÇ °¨°¢ÀÌ °¨¼ÒÇϰųª ºÎÁ·ÇØÁö°í, °¢¸· ¼¼Æ÷ÀÇ ¼Õ»óÀ» º¹±¸ÇÏ°í »ýÁ¸À» º¸ÀåÇÏ´Â µ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÏ´Â ¹°ÁúÀÇ »ý»êÀÌ °¨¼ÒÇÕ´Ï´Ù.

½Å°æ¿µ¾ç¼º °¢¸·¿°(NK)ÀÇ Áø´ÜÀº ¾î·ÆÁö¸¸, Áúº´ÀÇ ÁøÇàÀ» ¸·±â À§Çؼ­´Â Á¶±â¿¡ ¹ß°ßÇÏ´Â °ÍÀÌ Áß¿äÇÕ´Ï´Ù. NK Ä¡·áÀÇ ÁÖ¿ä ¸ñÇ¥´Â »óÇÇÀÇ ¹«°á¼ºÀ» À¯ÁöÇÏ°í »óÇÇÀÇ Ä¡À¯¸¦ ÃËÁøÇÏ°í °¢¸· Àå¾ÖÀÇ ÁøÇàÀ» ¿¹¹æÇÏ´Â °ÍÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ¸ñÇ¥¸¦ ´Þ¼ºÇϱâ À§Çؼ­´Â Á¶±â Áø´Ü, ÁßÁõµµ¿¡ µû¸¥ Ä¡·á ¹× ºó¹øÇÑ ¸ð´ÏÅ͸µÀÌ Áß¿äÇÕ´Ï´Ù. NKÀÇ Ä¡·á´Â ¾È±¸ À±È°À» À§ÇÑ À±È° Á¡¾È, Ãʰ¨¿°À» ¿¹¹æÇϱâ À§ÇÑ ±¹¼Ò Ç×»ýÁ¦, Ä¡À¯¸¦ ÃËÁøÇÏ°í »óÇÇÀÇ ¹«°á¼ºÀ» À¯ÁöÇϱâ À§ÇÑ Á¡¾ÈÁ¦³ª Á© µî ħ½À¼ºÀÌ ³·Àº ¾à¸®ÇÐÀû ¼±Åÿ¡¼­ ½ÃÀÛÇϰí ÀÚ¿¬½º·¯¿î ÇüÅ·Π¼øÂ÷ÀûÀ¸·Î ÀÌ·ç¾îÁö´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. ³­Ä¡¼º Áõ»óÀ̳ª Áø´Ü ½Ã º´¼¼°¡ ÁøÇàµÇ´Â °æ¿ì¿¡´Â º¸´Ù ħ½ÀÀûÀÌ°í ºñ¾à¸®ÇÐÀû Ä¡·á°¡ ÇÊ¿äÇÕ´Ï´Ù. ¿©±â¿¡´Â Ä¡·á¿ë ÄÜÅÃÆ®·»Áî, ¾ç¸· À̽Ä(AMT), Á¤¸³Á¾ ÀýÁ¦¼ú(¿µ±¸Àû ¶Ç´Â ÀϽÃÀû), °á¸· Ç÷¦ µîÀÌ Æ÷ÇԵ˴ϴÙ.

¼¼°èÀÇ ½Å°æ¿µ¾ç¼º °¢¸·¿°(NK, Neurotrophic Keratitis) ½ÃÀå¿¡ ´ëÇØ Á¶»çÇßÀ¸¸ç, ½ÃÀå ÇöÀç »óȲ/Áúº´ °³¿ä ¹× Ä¡·á¹ý/ȯÀÚ µ¿Çâ/Áö¿ªº° µ¿Çâ µîÀ» Á¦°øÇÕ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½Å°æ¿µ¾ç¼º °¢¸·¿°(NK) ÁúȯÀÇ ¹è°æ

Á¦3Àå ½Å°æ¿µ¾ç¼º °¢¸·¿°(NK)ÀÇ Áø´Ü

Á¦4Àå ¿ªÇÐ ¹× ȯÀÚ Áý´Ü

Á¦5Àå ÇöÀçÀÇ Ä¡·á¹ý ¹× ÀÇ·á ÇàÀ§

Á¦6Àå ½Å°æ¿µ¾ç¼º °¢¸·¿°(NK) ȯÀÚ µ¿Çâ

Á¦7Àå ¹Ì±¹, EU 4°³±¹, ¿µ±¹, ÀϺ»¿¡¼­ ¹ÌÃæÁ· ¿ä±¸

Á¦8Àå Ãâ½Ã°¡ ³¡³­ Ä¡·á¹ý

Á¦9Àå »õ·Î¿î Ä¡·á¹ý

Á¦10Àå ½Å°æ¿µ¾ç¼º °¢¸·¿°(NK)ÀÇ Ã³¹æ ÆÐÅÏ

Á¦11Àå ½Å°æ¿µ¾ç¼º °¢¸·¿°(NK)-°¡°Ý°ú »óȯ

Á¦12Àå ÇâÈÄ Ä¡·á ÆÐ·¯´ÙÀÓ

Á¦13Àå ÇöÇà ¹× ½Å±Ô Ä¡·áÀÇ ¿¬°£ ºñ¿ë

Á¦14Àå ½Å°æ¿µ¾ç¼º °¢¸·¿°(NK)¿¡¼­ Èıâ Ä¡·áÀÇ Àü·«Àû °í·Á »çÇ×

Á¦15Àå ½ÃÀå Àü¸Á

Á¦16Àå ±¹°¡º° ½ÃÀå ¿¹Ãø

Á¦17Àå ½ÃÀå ¼ºÀå ÃËÁø ¹× ¾ïÁ¦¿äÀÎ

Á¦18Àå ºÎ·Ï

LYJ
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The Neurotrophic Keratitis (NK) market is hugely contributed by the first and only approved therapy Oxervate/cenegermin and supportive treatments like preservative-free artificial tears, ointments and more. By 2034, the uptake of novel emerging therapies will serve as a major breakpoint to get a drastic change in the Neurotrophic Keratitis (NK) therapeutics market. The sales of the emerging therapies for the treatment Neurotrophic Keratitis (NK) in the study countries (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) will experience high growth over the 2020-2034 study period, with 11% CAGR.

"One of the major obstacles in treating neurotrophic keratitis is once there is damage to the corneal nerves, there is impairment of those vital functions, which creates a significant disruption to the ocular surface. Most of these treatments are supportive and only stabilize the surface."

Neurotrophic keratitis, also known as neurotrophic keratopathy, is a degenerative disease characterized by decreased corneal sensitivity and poor corneal healing. This disorder leaves the cornea susceptible to injury and decreases reflex tearing. Epithelial breakdown can lead to ulceration, infection, melting, and perforation secondary to poor healing.

Patients with neurotrophic keratitis have damage to the trigeminal nerve. This results in reduced or lack of sensation in the cornea, and reduced production of the substances that play a vital role in repairing damage and ensuring survival of cornea cells.

Neurotrophic keratitis (NK) can be challenging to diagnose, but it is crucial to identify it early to prevent disease progression. The primary goals of treatment for NK are to preserve epithelial integrity, promote epithelial healing, and prevent the progression of corneal damage. Early diagnosis, severity-based treatment, and frequent monitoring are crucial for achieving these goals. The treatment of NK is often sequential in nature, starting with less invasive pharmacological options such as lubricant eye drops for eye lubrication, topical antibiotics to prevent super-infections, and eye drops or gels to promote healing and preserve epithelial integrity. In refractory cases or those with advanced disease at diagnosis, more invasive, non-pharmacological treatment alternatives may be required. These can include therapeutic contact lenses, amniotic membrane transplantation (AMT), tarsorrhaphy (permanent or temporary), or conjunctival flap.

Mellalta's Neurotrophic Keratitis (NK) Report- Market Summary

Market Size 2034: $2.4 billion

CAGR%: 11%

Key Market Players: RegeneRx Biopharmaceuticals/ReGenTree/HLB Therapeutics; BRIM Biotechnology; Recordati; Claris Biotherapeutics; Neuroptika

Forecast Period: 2020-2034

Countries Covered: US, France, Germany, Italy, Spain, UK, China, and Japan.

Current SOC: Nerve Growth Factor; Preservative free antibiotics; Artificial eye drops; Ointments; Surgical Interventions

Future SOC: NGF; HGF; Regenerative therapies

Key Unmet Need: Lack of restorative treatments for neurotrophic keratitis and early diagnosis; Variability in Clinical Practice

Key Insights: Approval of Cenegermin /Oxervate (Dompe) changed the treatment landscape by targeting underlying pathology with upto 72% patient achieving complete corneal healing at 8 weeks.

Provider-Patient (PPP) Perspective: Cost-effectiveness of treatment; Better Diagnostic Identification; Access to appropriate treatments and improved options

Mellalta's Neurotrophic Keratitis (NK) Report - Epidemiology

The total prevalent cases of Neurotrophic Keratitis (NK) in the G7 countries are anticipated to increase by a significant number of cases by 2034 for the study period (2020-2034). As per estimates, the United States will present with the highest prevalence of Neurotrophic Keratitis (NK) cases in 2034. Among the EU5, Germany had the highest Neurotrophic Keratitis (NK) cases, followed by France, Italy, Spain, and UK. Japan is reported to have the highest number of treated cases after the United States, Germany, France, and Italy.

Mellalta's Neurotrophic Keratitis (NK) Report - Current Market Size & Forecast Trends

The Neurotrophic Keratitis (NK) therapeutics market is expected to experience high growth throughout our study period (i.e., 2020 to 2034) with a CAGR of 11%. The United States captured the highest market share as compared to the European 5 countries and Japan.

The current standard of care is limited to therapies such as Artificial Tears, Autologous Serum Drops (SED), Corneal Neurotization/PK, and Amniotic Membrane Transplantation (AMT). Initial interventions advocate the cessation of corneal-sensitivity-reducing therapies, favoring instead preservative-free artificial tears and lubricant ointments. While the efficacy of topical corticosteroids in NK is debated due to potential adverse effects, emerging heparin sulfate biomimetic matrix regenerating agents offer promising prospects, demonstrating remarkable corneal healing and antiviral properties. The focus shifts to averting corneal ulcer development and promoting epithelial repair in NK Stage 2 and reduce corneal stromal scarring and prevent possible perforations in NK Stage 3.

Cenegermin, containing recombinant human nerve growth factor (rhNGF), marks a breakthrough, becoming the first FDA-approved drug for NK treatment in 2018. Clinical trials reveal its efficacy in promoting corneal healing, with patients exhibiting significant improvement compared to vehicle-treated counterparts. Moreover, its favorable safety profile underscores its potential as a cornerstone therapy. Apart from promoting corneal epithelial wound healing, cenegermin 20 ¥ìg/ml shows significant improvement in corneal sensitivity and in visual acuity with minor side effects. Moreover, findings suggest that cenegermin 20 ¥ìg/ml is also effective in pediatric patients.

In the 2024-2034 forecast period, there will be tremendous growth and shift in therapeutic market with the launch of novel emerging therapies like Timbetasin/RGN-259 (RegeneRx Biopharmaceuticals/ReGenTree/HLB Therapeutics), BRM424 (BRIM Biotechnology), REC 0/0559 (Recordati), CSB-001 (Claris Biotherapeutics), and NRO-1 (Neuroptika). The emerging therapies will likely compete with and replace existing treatments, reflecting a dynamic shift towards more advanced therapeutic options in the Neurotrophic Keratitis space and more.

Questions Answered

What is the size of clinically and commercially relevant drug-treatable Neurotrophic Keratitis (NK) populations, and how will drug-treatment rates change over time?

Potential challenges and opportunities in implementing approved therapy for Neurotrophic Keratitis (NK).

What are the most promising agents in the pipeline, and how will they shape the future of this therapy market?

What key drivers and constraints will affect the Neurotrophic Keratitis (NK) therapy market over the forecast period?

Report Highlights

Neurotrophic Keratitis (NK) - Current Market Trends

Neurotrophic Keratitis (NK) - Current & Forecasted Cases across the G7 Countries

Neurotrophic Keratitis (NK) - Market Opportunities and Sales Potential for Agents

Neurotrophic Keratitis (NK) - Patient-based Market Forecast to 2034

Neurotrophic Keratitis (NK) - Untapped Business Opportunities

Neurotrophic Keratitis (NK) - Product Positioning Vis-a-vis Competitors' Products

Neurotrophic Keratitis (NK) - KOLs Insight

Table of Content

1.Executive Summary

2.Neurotrophic Keratitis (NK) Disease Background

3.Neurotrophic Keratitis (NK) Diagnosis

4.Epidemiology and Patient Populations

5.Current Therapies and Medical Practice

6.Patient Journey in Neurotrophic Keratitis (NK)

7.Unmet Needs in US, EU4, UK, and JP

8.Marketed Therapies Chapters

9.Emerging Therapies

10.Prescription Pattern in Neurotrophic Keratitis (NK)

11.Neurotrophic Keratitis (NK) - Pricing & Reimbursement

12.Future Treatment Paradigm

13.Annual Cost of Current & Emerging Treatment

14.Late Phase Therapies Strategic Considerations in Neurotrophic Keratitis (NK)

15.Market Outlook

16.Market Forecast by Country

17.Market Drivers and Constraints

18.Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â